Your position
We are looking for an ambitious postdoctoral researcher to study antibiotic efficacy against
non-tuberculous mycobacteria (NTM) in a physiologically relevant human airway infection model. The position is shared between the
Boeck Lab (DBM) and the
Jenal Lab (Biozentrum), is embedded in the NCCR AntiResist research network, and includes a close collaboration with A&J Science, a company advancing new antibacterial compounds.
The projectPulmonary NTM infections are increasing worldwide and remain notoriously difficult to cure. How NTM colonise and persist in human airways and how they respond to antibiotics in tissue remains poorly understood. The Jenal Lab has established a fully differentiated air-liquid interface (ALI) human airway model and used it to dissect how
Pseudomonas aeruginosa breaches the respiratory barrier (
Nature Microbiology 2024). The Boeck Lab has developed large-scale imaging approaches to measure antibiotic killing dynamics across NTM strains and drugs, linking drug tolerance to bacterial genotypes and clinical outcome (
Nature Microbiology 2026). This project brings both platforms together to establish NTM infection in human airway tissues and build a tissue-based drug efficacy platform for antimycobacterial compounds.
Your roleYou will establish NTM infection in human ALI airway epithelium and characterise infection dynamics. Building on this, you will develop and validate a tissue-based antibiotic efficacy platform, measuring bacterial growth and killing dynamics, intracellular drug activity, and tissue integrity during treatment. You will test novel antimicrobial compounds alongside standard-of-care antibiotics and compare tissue-based efficacy with conventional drug testing. You will lead the project scientifically and work at the interface of two academic labs and an industry partner.